NICE recommends Stelara (ustekinumab) for Psoriatic Arthritis- Johnson & Johnson
The National Institute for Health and Care Excellence (NICE) will recommend Stelara (ustekinumab), used as monotherapy or in combination with methotrexate, for treating the psoriatic arthritis in adults who have not responded to other therapies--such as AbbVie's Humira and Pfizer's Enbrel . Stelara first won NICE's approval back in December 2014 after Johnson & Johnson offered cost-effective discounts to NICE. Stelara had been rejected nearly 9 months earlier and the company agreed to cover the therapy under a "patient-access scheme," adding to Stelara's NICE recommendation for plaque psoriasis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.